Jamie Raskin actually said...
Your company has made more than $34 billion--$34 billion--from Copaxone but it reported to the committee that it has spent two percent of that on R&D expenditures for Copaxone patients.
Context
Raskin highlights the disparity between profits and R&D spending on a drug.
09/29/2020